The effect of dolutegravir on obstetrical outcomes among women living with HIV : A retrospective cohort study
Journal of Obstetrics and Gynaecology Research · 2025-06 · 51 (6)
DOI: 10.1111/jog.16349 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 22.06.2025. Verfasst von Ammar Al Naimi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, Oxazines, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To assess the effect of dolutegravir (DTG) on obstetrical outcomes for women living with HIV (WLWH).
Methods
This retrospective cohort study evaluated adult WLWH in antenatal care between 2016 and 2022 at two Nigerian centers. Patients were stratified into three antiretroviral therapy (ART) exposure groups: non‐DTG ART, DTG‐switch, and DTG. Multivariate linear and logistic regression models were utilized to assess the association between the type of ART and gestational weight gain (GWG), small for gestational age (SGA), gestational hypertension, and preterm birth.
Results
The study included 1839 (77.1%) non‐DTG users, 359 (15%) DTG users, and 188 (7.9%) DTG switchers. The adjusted association between DTG exposure and GWG was 0.72 (−0.08, 1.53) kg and 0.51 (−0.51, 1.54) kg for the DTG and DTG‐switch groups, respectively, compared to other ARTs. The adjusted odds ratios for gestational hypertension were 0.47 (0.09, 2.49) and 1.31 (0.43, 4.02), 0.57 (0.22, 1.52) and 0.73 (0.25, 2.10) for preterm birth, and 0.55 (0.25, 1.20) and 0.26 (0.08, 0.83) for SGA in DTG and DTG‐switch, respectively, compared to other ARTs.
Conclusions
DTG therapy is not associated with the risk of gestational hypertension nor preterm birth, and antenatal ART switching to DTG decreases the risk of growth restriction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Obstetrics and Gynecology, Buergerhospital, Frankfurt, Germany.
- Department of Obstetrics and Perinatal Medicine, Goethe University Hospital of Frankfurt, Frankfurt, Germany.
- Brigham & Women's Hospital, Boston, Massachusetts, USA.
- APIN Public Health Initiatives, Abuja, Nigeria.
ORCID-Profile: Ammar Al Naimi, Phyllis Kanki
Zitieren
APA
Al Naimi, A., Chang, C., Rawizza, H., Olaifa, O., Ogunsola, O., Okonkwo, P., & Kanki, P. (2025). The effect of dolutegravir on obstetrical outcomes among women living with HIV : A retrospective cohort study. Journal of Obstetrics and Gynaecology Research, 51(6). https://doi.org/10.1111/jog.16349
Vancouver
Al Naimi A, Chang C, Rawizza H, Olaifa O, Ogunsola O, Okonkwo P, et al. The effect of dolutegravir on obstetrical outcomes among women living with HIV : A retrospective cohort study. Journal of Obstetrics and Gynaecology Research. 2025;51(6). doi:10.1111/jog.16349
BibTeX
@article{AlNaimi2025,
author = {Al Naimi, Ammar and Chang, Charlotte and Rawizza, Holly and Olaifa, Oluwaseun and Ogunsola, Olabanjo and Okonkwo, Prosper and Kanki, Phyllis},
title = {The effect of dolutegravir on obstetrical outcomes among women living with HIV : A retrospective cohort study},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
volume = {51},
number = {6},
doi = {10.1111/jog.16349}
}
EUVIMED